Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCL-DDS Dexamethasone for Recurrent Cystoid Macular Edema
NCT04225611Phase 2Recruiting
- Sponsor
- Massachusetts Eye and Ear
- Start
- Mar 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone iontophoretic patch in cystoid macular edema (CME), sponsored by Massachusetts Eye and Ear. Primary endpoints: Occurrence of Contact Lens Related Ocular Infection at 28 days, Occurrence of Corneal epithelial Defect at 28 days and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
dexamethasone iontophoretic patch
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on NCT04225611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225611.